CVKD Stock Overview
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Cadrenal Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.45 |
| 52 Week High | US$3.14 |
| 52 Week Low | US$0.36 |
| Beta | 0 |
| 1 Month Change | -26.58% |
| 3 Month Change | -67.77% |
| 1 Year Change | -62.75% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -88.97% |
Recent News & Updates
Shareholder Returns
| CVKD | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 6.1% | 3.0% | -0.7% |
| 1Y | -62.7% | 12.5% | 22.8% |
Return vs Industry: CVKD underperformed the US Pharmaceuticals industry which returned 11.6% over the past year.
Return vs Market: CVKD underperformed the US Market which returned 22.3% over the past year.
Price Volatility
| CVKD volatility | |
|---|---|
| CVKD Average Weekly Movement | 14.4% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CVKD's share price has been volatile over the past 3 months.
Volatility Over Time: CVKD's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2022 | 4 | Quang Pham | www.cadrenal.com |
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Cadrenal Therapeutics, Inc. Fundamentals Summary
| CVKD fundamental statistics | |
|---|---|
| Market cap | US$7.04m |
| Earnings (TTM) | -US$8.36m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs CVKD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CVKD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$8.36m |
| Earnings | -US$8.36m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.52 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CVKD perform over the long term?
See historical performance and comparison